Mirae Asset Global Investments Co. Ltd. Sells 2,340 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mirae Asset Global Investments Co. Ltd. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 53,086 shares of the biopharmaceutical company's stock after selling 2,340 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Regeneron Pharmaceuticals were worth $33,281,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $25,000. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares in the last quarter. OFI Invest Asset Management purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $28,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares in the last quarter. Finally, Avalon Trust Co purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth $36,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN remained flat at $521.00 during trading on Friday. 1,607,735 shares of the stock were exchanged, compared to its average volume of 899,578. The company has a market capitalization of $56.25 billion, a price-to-earnings ratio of 13.26, a PEG ratio of 1.91 and a beta of 0.31. The business's 50-day simple moving average is $554.18 and its two-hundred day simple moving average is $631.95. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The business's revenue was down 3.7% compared to the same quarter last year. During the same period last year, the business posted $9.55 earnings per share. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.68%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Analyst Ratings Changes

Several brokerages have commented on REGN. The Goldman Sachs Group decreased their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. Finally, Royal Bank Of Canada cut shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price target on the stock. in a research note on Friday, May 30th. One research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $822.58.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.